Dawson James analyst Jason Kolbert initiated coverage of Zomedica with a Buy rating and $6 price target. Zomedica is positioning itself as leading supplier of a wide range of products-services to the multi-billion-dollar global veterinary marketplace, Kolbert tells investors in a research note. The analyst says recent acquisitions combined with cash on the balance sheet position the company to establish itself as a leader in the vet marketplace.
Published first on TheFly
